Skip to main content

Table 3 Distribution of PfCRT and PfMDR1 haplotypes in the study population 2003 – 2006

From: Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy

 

Year

 

2003

2004

2005

2006

TOTAL

PfCRT amino acid positions 72–76

 CVMNK only

0.0% (0)

3.4% (4)

7.9% (6)

0% (0)

4.3% (10)

 CVIET only

96.9% (31)

94.9% (111)

89.5% (68)

100% (9)

93.6% (219)

 CVMNK & CVIET mixed

3.1% (1)

1.7% (2)

2.6% (2)

0% (0)

2.1% (5)

  Number of samples

32

117

76

9

234

PfMDR1 amino acid positions 86, 184, 1042, 1246

 YYNY only

67.7% (12)

67.8% (59)

66.2% (43)

75% (6)

67.4% (120)

 YYNY mixed*

5.6% (1)

11.5% (10)

9.2% (6)

0.0% (0)

9.6% (17)

 YYND only

16.7% (3)

10.3% (9)

13.8% (9)

12.5% (1)

12.4% (22)

 YYND mixed**

0.0% (0)

10.3% (9)

7.7% (5)

0.0% (0)

7.9% (14)

 Other haplotypes

11.1% (2)

6.9% (6)

9.2% (6)

12.5% (1)

8.4% (15)

  Number of samples

18

87***

65***

8

178***

  1. *Mixed with codons of other haplotypes, including 10 YYND (6 in 2004; 4 in 2005).
  2. **Mixed with codons of other haplotypes, including 10 YYNY (6 in 2004; 4 in 2005).
  3. ***Total is corrected for the YYNY + YYND mixed samples that are entered twice, as both YYNY mixed and as YYND mixed samples.